FDA Rescinds June 2022 Marketing Denial Orders For JUUL Labs
Portfolio Pulse from Benzinga Newsdesk
The FDA has rescinded its June 2022 marketing denial orders for JUUL Labs, returning JUUL's applications to pending status under FDA review. This action is prompted by new case law and additional information from JUUL. The rescission is neither an authorization nor a denial.
June 06, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Altria Group, Inc. (MO), which owns a significant stake in JUUL Labs, may see short-term volatility due to the FDA's decision to rescind the marketing denial orders for JUUL. The pending status of JUUL's applications introduces uncertainty.
Altria's stake in JUUL means that regulatory decisions affecting JUUL can impact Altria's stock. The rescission introduces uncertainty, which may lead to short-term volatility.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Philip Morris International Inc. (PM) may experience indirect effects from the FDA's decision on JUUL, as regulatory actions in the e-cigarette market can influence the broader tobacco industry.
While Philip Morris does not have a direct stake in JUUL, regulatory actions in the e-cigarette market can have broader implications for the tobacco industry, potentially affecting PM.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50